Tiago Fauth
Stock Analyst at Wells Fargo
(2.05)
# 2,886
Out of 4,876 analysts
139
Total ratings
37.84%
Success rate
-7.15%
Average return
Main Sectors:
Stocks Rated by Tiago Fauth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRNA Verona Pharma | Maintains: Overweight | $107 → $138 | $93.82 | +47.09% | 6 | Jun 20, 2025 | |
| LQDA Liquidia | Maintains: Overweight | $23 → $25 | $13.10 | +90.84% | 2 | Jun 12, 2025 | |
| INSM Insmed | Maintains: Overweight | $107 → $119 | $99.49 | +19.61% | 5 | Jun 11, 2025 | |
| SVRA Savara | Maintains: Overweight | $8 → $7 | $2.21 | +216.74% | 2 | May 28, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $68 → $74 | $49.84 | +48.48% | 2 | May 27, 2025 | |
| INZY Inozyme Pharma | Downgrades: Equal-Weight | $4 | $3.99 | +0.25% | 3 | May 16, 2025 | |
| UTHR United Therapeutics | Downgrades: Equal-Weight | $395 → $314 | $284.27 | +10.46% | 5 | Apr 25, 2025 | |
| TECX Tectonic Therapeutic | Maintains: Overweight | $112 → $101 | $19.80 | +410.10% | 4 | Mar 21, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $275 → $287 | $322.83 | -11.10% | 5 | Mar 21, 2025 | |
| PLRX Pliant Therapeutics | Maintains: Equal-Weight | $4 → $3 | $1.25 | +140.00% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $13.49 | +92.74% | 6 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $17 | $5.93 | +186.68% | 1 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $88 | $36.52 | +140.96% | 7 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $3.76 | +139.36% | 1 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $22 | $6.67 | +229.84% | 2 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $75 | $54.50 | +37.61% | 1 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $62 | $2.34 | +2,549.57% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $89 | $172.14 | -48.30% | 16 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $51 | $14.33 | +255.90% | 3 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $120 | $55.17 | +117.51% | 7 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $4 | $16.10 | -75.16% | 4 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $2.62 | +434.35% | 4 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $5.67 | +358.55% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $28 | $3.61 | +675.62% | 7 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $81 | $17.43 | +364.72% | 11 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $0.38 | +1,983.33% | 5 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.10 | +1,172.73% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $34 | $0.41 | +8,278.51% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $150 | $3.42 | +4,285.96% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $43.67 | -33.59% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $1.70 | +664.71% | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $13 | $2.28 | +470.18% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2.5 → $2 | $0.81 | +147.59% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $297 → $340 | $560.14 | -39.30% | 3 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $265 → $259 | $277.13 | -6.54% | 1 | Apr 28, 2021 |
Verona Pharma
Jun 20, 2025
Maintains: Overweight
Price Target: $107 → $138
Current: $93.82
Upside: +47.09%
Liquidia
Jun 12, 2025
Maintains: Overweight
Price Target: $23 → $25
Current: $13.10
Upside: +90.84%
Insmed
Jun 11, 2025
Maintains: Overweight
Price Target: $107 → $119
Current: $99.49
Upside: +19.61%
Savara
May 28, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $2.21
Upside: +216.74%
PTC Therapeutics
May 27, 2025
Maintains: Overweight
Price Target: $68 → $74
Current: $49.84
Upside: +48.48%
Inozyme Pharma
May 16, 2025
Downgrades: Equal-Weight
Price Target: $4
Current: $3.99
Upside: +0.25%
United Therapeutics
Apr 25, 2025
Downgrades: Equal-Weight
Price Target: $395 → $314
Current: $284.27
Upside: +10.46%
Tectonic Therapeutic
Mar 21, 2025
Maintains: Overweight
Price Target: $112 → $101
Current: $19.80
Upside: +410.10%
Alnylam Pharmaceuticals
Mar 21, 2025
Maintains: Equal-Weight
Price Target: $275 → $287
Current: $322.83
Upside: -11.10%
Pliant Therapeutics
Mar 4, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $1.25
Upside: +140.00%
Feb 27, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $13.49
Upside: +92.74%
Feb 20, 2025
Maintains: Overweight
Price Target: $18 → $17
Current: $5.93
Upside: +186.68%
Dec 20, 2024
Maintains: Overweight
Price Target: $75 → $88
Current: $36.52
Upside: +140.96%
Dec 20, 2024
Initiates: Overweight
Price Target: $9
Current: $3.76
Upside: +139.36%
Oct 16, 2024
Maintains: Overweight
Price Target: $11 → $22
Current: $6.67
Upside: +229.84%
Aug 22, 2024
Initiates: Overweight
Price Target: $75
Current: $54.50
Upside: +37.61%
Aug 11, 2023
Maintains: Outperform
Price Target: $63 → $62
Current: $2.34
Upside: +2,549.57%
Jun 14, 2023
Assumes: Neutral
Price Target: $89
Current: $172.14
Upside: -48.30%
Jun 14, 2023
Assumes: Outperform
Price Target: $51
Current: $14.33
Upside: +255.90%
Jun 14, 2023
Assumes: Outperform
Price Target: $120
Current: $55.17
Upside: +117.51%
May 23, 2023
Reiterates: Underperform
Price Target: $4
Current: $16.10
Upside: -75.16%
May 16, 2023
Reiterates: Outperform
Price Target: $14
Current: $2.62
Upside: +434.35%
May 11, 2023
Reiterates: Outperform
Price Target: $26
Current: $5.67
Upside: +358.55%
May 5, 2023
Maintains: Outperform
Price Target: $34 → $28
Current: $3.61
Upside: +675.62%
May 5, 2023
Maintains: Neutral
Price Target: $70 → $81
Current: $17.43
Upside: +364.72%
Mar 24, 2023
Reiterates: Neutral
Price Target: $8
Current: $0.38
Upside: +1,983.33%
Mar 23, 2023
Reiterates: Outperform
Price Target: $14
Current: $1.10
Upside: +1,172.73%
Mar 10, 2023
Maintains: Outperform
Price Target: $38 → $34
Current: $0.41
Upside: +8,278.51%
Mar 10, 2023
Reiterates: Outperform
Price Target: $150
Current: $3.42
Upside: +4,285.96%
Jan 26, 2023
Initiates: Outperform
Price Target: $29
Current: $43.67
Upside: -33.59%
Dec 16, 2022
Initiates: Outperform
Price Target: $13
Current: $1.70
Upside: +664.71%
Nov 18, 2022
Downgrades: Neutral
Price Target: $25 → $13
Current: $2.28
Upside: +470.18%
May 13, 2022
Maintains: Underperform
Price Target: $2.5 → $2
Current: $0.81
Upside: +147.59%
Dec 20, 2021
Maintains: Neutral
Price Target: $297 → $340
Current: $560.14
Upside: -39.30%
Apr 28, 2021
Maintains: Outperform
Price Target: $265 → $259
Current: $277.13
Upside: -6.54%